Products for Research Use Only
RegisterLogin

Muvalaplin

CAT: 0804-HY-152857-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-152857-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Muvalaplin (LY3473329) is an orally active, selective small molecule inhibitor of lipoprotein (a) (Lp (a) ) that disrupts the initial non-covalent interaction between apo (a) and apoB100, preventing the disulphide bond and Lp (a) formation. Muvalaplin reduces the levels of Lp (a) in transgenic mice and in cynomolgus monkeys[1][2][3][4][5].
CAS Number
2565656-70-2
Product Name Alternative
LY3473329
UNSPSC
12352005
Target
LDLR
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/muvalaplin.html
Purity
99.96
Solubility
DMSO : 22.22 mg/mL (ultrasonic; adjust pH to 7 with 1 M HCl)
Smiles
OC([C@H]([C@H]1CCNC1)CC2=CC(CN(CC3=CC(C[C@@H]([C@H]4CCNC4)C(O)=O)=CC=C3)CC5=CC(C[C@@H]([C@H]6CCNC6)C(O)=O)=CC=C5)=CC=C2)=O
Molecular Formula
C42H54N4O6
Molecular Weight
710.90
References & Citations
[1]Bhatia HS, et al. Lipoprotein (a) : Evidence for Role as a Causal Risk Factor in Cardiovascular Disease and Emerging Therapies. J Clin Med. 2022 Oct 13;11 (20) :6040.|[2]Nicholls SJ, et al. Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein (a) Formation: A Randomized Clinical Trial. JAMA. 2023 Sep 19;330 (11) :1042-1053.|[3]Diaz N, et al. Discovery of potent small-molecule inhibitors of lipoprotein (a) formation. Nature. 2024 May;629 (8013) :945-950.|[4]Hooper AJ, et al. Potential of muvalaplin as a lipoprotein (a) inhibitor. Expert Opin Investig Drugs. 2024 Jan;33 (1) :5-7.|[5]Norata GD, et al. Oral strategies to target proprotein convertase subtilisin/kexin type 9 and lipoprotein (a) : the new frontier of lipid lowering. Eur Heart J. 2023 Dec 21;44 (48) :5018-5020.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2

Alternative Products

CatalogName
M37059-01Muvalaplin
GTR19238927-01Muvalaplin tetrahydrochloride
E1691-25mgMuvalaplin (LY3473329)
GTR19216182-01LY3473329 (Muvalaplin)

Popular Products